Overlap syndromes involving myasthenia gravis, myositis and myocarditis are recognised adverse effects of immune checkpoint inhibitors (ICI). We report a similar syndrome of myasthenia gravis and myositis in a patient without prior ICI exposure. Diagnostic tests showed signs of both immune-mediated necrotising myopathy and myasthenia gravis. Symptoms included proximal muscle weakness, ophthalmoplegia, bulbar symptoms and neuromuscular respiratory failure. Initial treatment with glucocorticoids and intravenous immunoglobulin for myositis was partially effective. Significant improvement occurred with rituximab and an acetylcholinesterase inhibitor. Although imaging had not revealed a thymic mass suggestive of thymoma, the patient underwent thymectomy several weeks after recovering from the acute illness. Histopathological examination of the resected tissue confirmed the presence of thymoma. This case illustrates that myasthenia gravis and myositis can spontaneously co-present. Clinicians should consider the possibility that a seemingly atypical presentation of a condition may reflect a more typical presentation of two conditions, such as in this case. In this situation, paraneoplastic causes should be considered.

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2024-262565DOI Listing

Publication Analysis

Top Keywords

myasthenia gravis
20
gravis myositis
12
myositis
5
myasthenia
5
gravis
5
global weakness
4
weakness clear
4
clear precipitant
4
precipitant thymoma
4
thymoma presenting
4

Similar Publications

Robotic gastrectomy is a safe and minimally invasive approach that may reduce the risk of complications in patients with severely impaired pulmonary function. Here, we report the successful treatment of an 80-year-old patient with gastric cancer and myasthenia gravis(MG)using perioperative respiratory rehabilitation and robotic gastrectomy with D2 lymphadenectomy. Patients with gastric cancer and severe pulmonary dysfunction are at a risk of postoperative respiratory disorders, including severe pneumonia.

View Article and Find Full Text PDF

BACKGROUND Cardiomyopathy associated with thymoma is thought to be a cardiac manifestations of myasthenia gravis (MG). However, there are case reports of newly diagnosed thymoma presenting with cardiomyopathy without MG, and the mechanism remains unclear. The purpose of this report is to explore tachycardia-induced cardiomyopathy (TIC) as a potential mechanism for cardiomyopathy in thymoma without features of MG.

View Article and Find Full Text PDF

Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable data.

Orphanet J Rare Dis

March 2025

Peripheral Nervous System and Muscle Department, Reference Center for Neuromuscular Disorders, Pasteur 2 Hospital, Centre Hospitalier, Universitaire de Nice, Nice University Hospital, SNPM - Hôpital Pasteur 2 - 30 voie Romaine, 06001, Nice CEDEX, France.

Background: Myasthenia gravis (MG) is a rare autoimmune disorder. Several new treatment concepts have emerged in recent years, but access to these treatments varies due to differing national reimbursement regulations, leading to disparities across Europe. This highlights the need for high-quality data collection by stakeholders to establish MG registries.

View Article and Find Full Text PDF

The causal association between pulmonary arterial hypertension (PAH) and autoimmune diseases remains uncertain. This study aimed to assess the causal associations between PAH and autoimmune diseases using bidirectional Mendelian randomization (MR) analyses. Genome-wide association summary statistics for PAH, asthma, myasthenia gravis, rheumatoid arthritis (RA), systemic lupus erythematosus, and type 1 diabetes mellitus were obtained from publicly accessible databases.

View Article and Find Full Text PDF

Economic burden of myasthenia gravis in China: a nationwide registry-based study.

Curr Med Res Opin

March 2025

Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China.

Background: The long-term treatment of myasthenia gravis (MG) and impaired productivity related to physical decline incur significant economic burdens on affected populations and society. This study aims to evaluate the costs of MG in China from a societal perspective and to identify the cost-driving factors.

Methods: A web-based survey was conducted on 1020 MG patients recruited through a national registry system in China.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!